Zobrazit minimální záznam

dc.contributor.authorJalůvka, František
dc.contributor.authorIhnát, Peter
dc.contributor.authorMaďarič, Juraj
dc.contributor.authorVrtková, Adéla
dc.contributor.authorJanošek, Jaroslav
dc.contributor.authorProcházka, Václav
dc.date.accessioned2021-02-03T09:52:13Z
dc.date.available2021-02-03T09:52:13Z
dc.date.issued2020
dc.identifier.citationInternational Journal of Molecular Sciences. 2020, vol. 21, issue 23, art. no. 8999.cs
dc.identifier.issn1422-0067
dc.identifier.urihttp://hdl.handle.net/10084/142634
dc.description.abstract(1) Background: The treatment of peripheral arterial disease (PAD) is focused on improving perfusion and oxygenation in the affected limb. Standard revascularization methods include bypass surgery, endovascular interventional procedures, or hybrid revascularization. Cell-based therapy can be an alternative strategy for patients with no-option critical limb ischemia who are not eligible for endovascular or surgical procedures. (2) Aims: The aim of this narrative review was to provide an up-to-date critical overview of the knowledge and evidence-based medicine data on the position of cell therapy in the treatment of PAD. The current evidence on the cell-based therapy is summarized and future perspectives outlined, emphasizing the potential of exosomal cell-free approaches in patients with critical limb ischemia. (3) Methods: Cochrane and PubMed databases were searched for keywords "critical limb ischemia and cell therapy". In total, 589 papers were identified, 11 of which were reviews and 11 were meta-analyses. These were used as the primary source of information, using cross-referencing for identification of additional papers. (4) Results: Meta-analyses focusing on cell therapy in PAD treatment confirm significantly greater odds of limb salvage in the first year after the cell therapy administration. Reported odds ratio estimates of preventing amputation being mostly in the region 1.6-3, although with a prolonged observation period, it seems that the odds ratio can grow even further. The odds of wound healing were at least two times higher when compared with the standard conservative therapy. Secondary endpoints of the available meta-analyses are also included in this review. Improvement of perfusion and oxygenation parameters in the affected limb, pain regression, and claudication interval prolongation are discussed. (5) Conclusions: The available evidence-based medicine data show that this technique is safe, associated with minimum complications or adverse events, and effective.cs
dc.language.isoencs
dc.publisherMDPIcs
dc.relation.ispartofseriesInternational Journal of Molecular Sciencescs
dc.relation.urihttp://doi.org/10.3390/ijms21238999cs
dc.rights© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.cs
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/cs
dc.subjectcell therapycs
dc.subjectperipheral arterial diseasecs
dc.subjectbone marrowcs
dc.subjectadipose tissuecs
dc.subjectmesenchymal stem cellscs
dc.subjectexosomecs
dc.subjectcritical limb ischemiacs
dc.titleCurrent status of cell-based therapy in patients with critical limb ischemiacs
dc.typearticlecs
dc.identifier.doi10.3390/ijms21238999
dc.rights.accessopenAccesscs
dc.type.versionpublishedVersioncs
dc.type.statusPeer-reviewedcs
dc.description.sourceWeb of Sciencecs
dc.description.volume21cs
dc.description.issue23cs
dc.description.firstpageart. no. 8999cs
dc.identifier.wos000597547800001


Soubory tohoto záznamu

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Kromě případů, kde je uvedeno jinak, licence tohoto záznamu je © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.